Certification Board of Infection Control and Epidemiology (CBIC) 2025 – 400 Free Practice Questions to Pass the Exam

Image Description

Question: 1 / 400

What is a significant risk when administering piperacillin/tazobactam and aminoglycosides together in the same IV?

Decreased effectiveness of both agents

Inactivation of both agents

The significant risk of inactivation of both agents when administering piperacillin/tazobactam and aminoglycosides together in the same IV is rooted in their chemical interaction. Piperacillin, a penicillin antibiotic, can react with aminoglycosides in an alkaline environment, such as that found in IV solutions. This interaction may lead to the formation of inactive complexes, reducing the efficacy of both antibiotics.

While aminoglycosides have a separate profile and mechanisms of action, the stability and activity of these drugs can be compromised when mixed together. Therefore, it’s crucial to administer these medications separately to maintain their effectiveness and achieve the desired therapeutic outcome.

Other factors, such as the potential for nephrotoxicity, underscore the importance of careful consideration in prescribing practices, but the specific concern of inactivation is paramount when these medications are combined in the same IV solution. Adhering to proper protocols when administering these agents facilitates optimal therapeutic effectiveness and minimizes the risks associated with drug interactions.

Get further explanation with Examzify DeepDiveBeta

Increased risk of nephrotoxicity

Prolonged half-life of aminoglycosides

Next Question

Report this question

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy